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negative health consequences. Micronutrient malnutrition, or “hidden hunger”, is an 
even more widespread problem, to which economic development and income growth 
alone are not expected to provide a solution any time soon. Existing micronutrient inter-
ventions like pharmaceutical supplementation or industrial fortification have their limi-
tations and can be complemented by a new approach: breeding food crops for higher 
micronutrient densities. Knowledge about the cost-effectiveness of this new tool, also 
termed biofortification, is scarce. In this study, a framework for economic impact analy-
sis is developed, which is then used for evaluation of iron-rich rice and wheat in India. 
Health benefits are measured and quantified using “disability-adjusted life years” 
(DALYs). The impact of biofortification is based on a representative data set of food 
consumption at the household level. Juxtaposing imputed health benefits with research 
and development costs proves the cost-effectiveness of the intervention; under pessimistic 
assumptions saving one healthy life year through biofortification only costs US$ 1.90, a 
cost which even declines to 36 Cents under optimistic assumptions. Extending the study 
to include a cost-benefit analysis shows that iron biofortification, with an internal rate of 
return of 74-152%, can also be a worthwhile public investment.  
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Despite the successes of the Green Revolution and continued efforts to fight poverty, 
hunger remains widespread, with an estimated 800m undernourished people in the devel-
oping world (United Nations SCN). The problem of “hidden hunger” – as micronutrient 
malnutrition is referred to – is, however, much larger. An estimated 3.5 billion people in 
developing countries are affected by iron deficiency (ID), 2.2 billion people suffer from 
iodine deficiency and over 250m children are affected by vitamin A deficiency (WHO 
1998, Underwood, United Nations ACC/SCN). The consequences of this hidden hunger – 
in terms of mortality, impaired physical and cognitive development, or eye problems – 
assume staggering magnitudes. 
While there is a correlation between hidden hunger and poverty, it is well-recognised that 
relying on economic development and income growth alone is not likely to rid the world 
of micronutrient malnutrition any time soon (Weinberger 2003, Haddad et al.). There are, 
however, several alternative interventions to fight micronutrient deficiencies. These 
include industrial fortification of foods (such as sugar, or wheat flour), pharmaceutical 
supplementation, the promotion of dietary diversification, and nutrition education. These 
interventions vary in terms of their potential coverage, monitoring and other costs, and 
the degree to which compliance is necessary (see table 1). However, with the exception 
of iodised salt, their success in developing countries has been mixed (Underwood; United 
Nations ACC/SCN; Cook, Skikne, and Baynes).  
Biofortification is a new approach that complements the existing “toolbox” of inter-
ventions. It refers to breeding staple food crops – which form the mainstay of the diet for 
large numbers of at-risk people – for higher micronutrient levels. Thus the strategy is  
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targeted at those who cannot afford a diet adequate in fruits, vegetables and meats, which 
are better sources of micronutrients. In principle, once such micronutrient-rich crops are 
developed and successfully disseminated, they automatically form part of the food chain. 
Hence, for a largely one-time investment this strategy can produce a constant stream of 
future benefits to consumers of these crops. Moreover, consumer acceptance of crops that 
are biofortified with iron and zinc, which are largely invisible traits, is not expected to be 
an issue. A comparison of the potential advantages of biofortification, relative to the 
other interventions, is contained in table 1. So far, there has been no systematic attempt to 
analyse the benefits and costs of this strategy; the present article attempts to do so. 
In particular, this article attempts to quantify the extent to which the biofortification 
strategy can help ameliorate ID. Since iron-rich wheat and rice varieties are still being 
developed and have not yet been disseminated, the quantification necessarily is ex ante in 
nature. We employ the “disability adjusted life years” (DALYs) framework, which 
gained currency as metric for measuring health outcomes. In departure from the received 
literature, however, this study models explicitly the functional consequences of ID. The 
focus of this article is on India, a country that is home to many of those suffering from 
micronutrient malnutrition. ID is the single largest micronutrient deficiency in India; 
about 50% of women are anaemic, as are 74% of children (IIPS).
1  
The following sections sets out the DALYs methodology, highlight the extensions and 
modifications to the way this framework is utilised, present estimates of the burden of ID 
in India, consider the potential reduction in this burden under 2 scenarios, quantify the  
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cost-effectiveness of biofortification, provide results of cost-benefit analyses, and 
compare these results with those of other interventions. 
Measuring health 
Since the 1990s, with the “World Development Report” (World Bank) and with “The 
Global Burden of Disease” study (GBD) by Murray and Lopez, DALYs have become 
increasingly popular to measure health: they are used not only to establish the burden of a 
disease in a particular region, but also more generally as a yardstick to capture and 
quantify a range of adverse effects on human life and health that have such different 
causes as communicable diseases (Mills and Shillcutt), sanitation and hygiene risks 
(Rijsberman), malnutrition (Behrman, Alderman, and Hoddinott) or civil war (Collier and 
Hoeffler). Quantifying the burden of vitamin A deficiency in the Philippines, Zimmer-
mann and Qaim were the first to employ this framework to analyse the benefits of bio-
fortification. 
Compared to other measures that are used to value health interventions, such as cost-of-
illness or willingness-to-pay approaches, DALYs do not rely on the financial capacity or 
the economic potential of the affected individuals; health is not valued differently for 
different individuals. Rather, it is quantified according to the severity of the health out-
comes in question and expressed in common units that combine both morbidity and 
premature mortality. This standardisation allows comparisons across different health out-
comes. The crucial element in this measure is the weighting of years of life lived with 
disabilities resulting from a specific disease; these severity weights (or “disability  
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weights”) can be in the range between 0 and 1, with 0 representing perfect health and 1 
representing a health status equal to death. Because DALYs capture the whole scope of a 
disease the approach also circumvents the shortcomings of proxy-measures, like mor-
tality, which might attract the attention of policy makers but divert resources from non-
fatal but more widespread health problems.  
The DALYs measure of the total burden of a disease is obtained as the sum of “years of 
life lost” (YLL) due to cause-specific mortality and the sum of “years lived with dis-
ability” (YLD), the latter of which are weighted (Murray and Lopez). That is,  
(1)   Burden of disease = DALYslost = YLL + YLD, where  
(2)   YLL = f (size of target group, mortality rate of disease, discount rate), and  
(3)   YLD = f (size of target group, incidence rate, disability weight, discount rate). 
Taking account of potentially different incidence rates and levels of severity of a disease 
between different groups within a population, and following Zimmermann and Qaim, the 
complete formula can be represented more formally as:  
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where Tj is the total number of people in target group j and Mij is the mortality rate asso-
ciated with the given disease i. Iij is the incidence rate of disease i that is of interest, Dij is 
the corresponding disability weight, and dij is the duration of the disease. For permanent 
disabilities dij equals the average remaining life expectancy Lj. Future life is discounted at 
the rate of r.   
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Applying this formula to analyse a disease or its sequelae yields the (current) burden of 
disease; interventions that change one of the components of the formula (in particular the 
incidence and mortality rates) result in a different (potential/future) burden of disease. 
The difference in DALYs between the current burden (“without” intervention) and the 
future burden (“with” intervention) then gives the health impact of the intervention in 
common units, i.e. “DALYs saved”.  
For this article, as a first step, the adverse health consequences of ID need to be specified. 
ID is defined in relation to body iron stores and haemoglobin concentrations; in its more 
severe manifestations it can take the form of iron deficiency anaemia (IDA). IDA is a 
subgroup of anaemia, which can also have other causes, like hookworms or malaria 
(Nestel and Davidsson). Anaemia can be classified as “mild”, “moderate”, and “severe”. 
The GBD uses moderate and severe IDA and, in addition, “cognitive impairment” in its 
calculation of DALYs. In our approach, we go beyond this classification and specify the 
burden of IDA on a “deeper” level, i.e., on the level of the actual functional outcomes 
that can be attributed to IDA. These are (i) impaired physical activity (Hallberg and 
Scrimshaw), (ii) impaired mental development (Nokes and Bundy), and (iii) maternal 
mortality, which leads to further negative outcomes such as increases in the number of 
stillbirths and child deaths that occur due to the lack of breastfeeding and care caused by 
the death of the mother (Rush).  
There is no robust scientific evidence that ID is linked to tangible adverse functional out-
comes up to a state of moderate IDA (Rush, Stoltzfus). Therefore we only calculate 
DALYs for functional outcomes that can be attributed to moderate or severe IDA. We did  
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not include any other adverse functional outcome, for which there is no scientific consen-
sus on the link between the disease and ID.
2 This means that the results derived from this 
exercise represent a lower bound of the burden of ID.  
The calculation of DALYs for impaired physical activity is carried out for moderate and 
severe manifestations and differentiated between the group of children under five, the 
group of children aged 6-14 years, the group of men and the group of women, to take 
account of different prevalence rates. DALYs for impaired mental development (for 
which permanent effects are assumed) are calculated for children under five and differ-
entiated according to moderate and severe manifestations. DALYs that are lost due to 
maternal mortality are based on the number of live births. Disability weights (DA-
weights) were discussed by the experts within the group of authors and based on those 
used by Murray and Lopez in the GBD (table 2).  
Before employing the DALYs method detailed above to quantify ID in India, it is 
important to recognise – and in some cases address – some of the criticisms made of this 
approach. The formula laid out differs from the “original” formula used by Murray in that 
it omits “age-weighting”, which acts to increase the burden of a disease if the disabling 
condition affects young, productive adults (as opposed to infants or the elderly). How-
ever, this implies an ethical value judgement, a social preference for certain age groups, 
and has been the subject of criticism (e.g., Anand and Hanson, Lyttkens, Richardson 
1999a, Williams). Other literature suggests that including social preferences based on 
personal characteristics could be justified, whether it is for utility or for equity reasons 
(Olsen et al.). Murray justifies the inclusion of an age-weighting term indeed by referring  
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to studies on the social and individual willingness-to-pay for health care, which give 
more weight to the contribution of young adults to (social and emotional) welfare. If this 
argument were to be followed further, it could imply, for instance, that the life and health 
of a physician or a celebrity would have a higher value than the life of, say, an unskilled 
labourer or an orphan, thus “opening a Pandora’s box” (Lyttkens). Therefore, in this 
analysis we exclude age-weighting. Note, however, that even so age plays a significant 
role in the calculations: saving the life of a child prevents the loss of more DALYs than 
saving the life of an older person, because of the longer remaining life expectancy.  
Another component of the DALYs calculations in the GBD, which has attracted criticism 
for its arbitrariness and for introducing a gender bias, was the assumed remaining life 
expectancy (Lyttkens). As the GBD intends to capture the burden of all diseases simulta-
neously, there is the need to assume a maximum “biological” life expectancy to be able to 
calculate the remaining (hypothetical) life expectancy in the absence of any disease or 
fatal incident. Murray based this maximum theoretical life expectancy on the life expec-
tancy of Japanese women, as this is the highest observed life expectancy in the world; 
men’s theoretical life expectancy was then put at a somewhat lower age because of 
“biological differences”. In effect, this amounts to introducing a “sex weight”, which 
implies that, ceteris paribus, interventions aimed at saving the lives of women save more 
DALYs. We use a standard life table for India (WHO 2001). This may be justified on 
grounds that changes in the prevalence of a single condition – in this case ID – are not 
expected to change average life expectancy significantly (Williams).  
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The DA-weights used to calculate DALYs have also attracted criticism on various 
grounds (Anand and Hanson; Lyttkens; Allotey et al.; Groce, Chamie, and Me; 
Richardson 1999b). These include: whether health experts are “better” able to determine 
these weights than members of the public; the assumed independence of the DA-weights 
regarding the context in which the disabling condition occurs;
3 and the apparent sys-
tematic bias against the permanently disabled. While such issues will likely continue to 
remain contentious, in this article, in determining the DA-weights for functional out-
comes related to ID, the context of developing countries was very clearly at the forefront. 
Furthermore, this article does not separately consider the health state of individuals 
(permanently disabled or healthy) in calculating the YLL.  
Another criticism of the DALYs formula is the discounting of future life years 
(Richardson 1999a; Lyttkens; Anand and Hanson). If future life years are discounted, 
present lives become relatively more valuable; this can serve to justify interventions that 
benefit the present generation at the expense of future generations. If the measurement of 
ill health becomes dependent on time the same illness causes a bigger loss of DALYs 
today than it does tomorrow. In short, discounting is deemed inequitable. Murray and 
Richardson (1999a) contain good overviews of these and related issues (such as opportu-
nity costs and the time paradox). We support the view that discounting of health benefits 
makes sense and follow the World Bank and Murray and apply a 3% discount rate in our 
calculations. However, given the sensitivity of the results to the choice of a discount rate, 
we also report a second set of results in table 9, which has been calculated without 
discounting of health benefits. Note that if the objective is to rank alternative interven- 
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tions, then discounting does not matter: if an intervention decreases a given burden of a 
disease by a certain percentage, then, for all practical purposes, the result will not change 
for different discount rates, as these are applied to both the with and without intervention 
alternatives.  
Another criticism of the DALY approach is that it focuses only on the health of affected 
individuals, but fails to take account of health care costs, of private care by relatives and 
friends, or of the anxiety of people close those affected (Lyttkens). Furthermore, DALYs 
can be seen to value human life – whether implicitly or explicitly – and to express the 
value of life simply as a positive function of health, thus failing to capture all dimensions 
of life, while at the same time passing over positive contributions of the ill and disabled 
and opening the doors for their exclusion (Arnesen and Nord; Groce, Chamie, and Me).  
Yet, all measures of ill health suffer from one limitation or another. For instance, the 
cost-of-illness approach focuses on health care costs and lost productivity only and, 
hence, attaches more value to richer or more productive individuals. DALYs – though not 
free of limitations despite our modifications – capture the burden of a disease in a trans-
parent and more equitable manner.  
The burden of iron deficiency in India 
The starting point for quantifying the burden of ID is information on the prevalence of 
anaemia. For India, anaemia prevalence rates are taken from current literature (IIPS and 
NIN) and, following Stein et al., transformed into incidence rates for IDA for the target 
groups used in this study (table 4). For maternal mortality it was assumed that 5% of total  
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maternal mortality, which was also taken from IIPS, is due to IDA.
4 The group sizes, i.e. 
the number of people in the target groups, are based on Census of India data (online at 
www.censusindia.net). The average remaining life expectancies used are taken from an 
Indian life table (WHO 2001).  
Applying these data to the DALY framework yields the current burden of ID in India: an 
annual loss of 4m healthy life years (3.7m of which are lost through morbidity and 
240,000 are lost due to mortality). Even though ID is already an acknowledged public 
health problem in India, this figure underlines the severity of this deficiency.  
Calculating the impact of biofortification 
By increasing the iron content of rice and wheat, biofortification is expected to increase 
iron intakes, and thereby to decrease the prevalence of ID and IDA. However, before 
making an assessment of the likely impact of an intervention such as biofortification, it is 
useful to review dietary patterns in India: cereal consumption in India is high; it averaged 
12.7 kg per capita per month (pcpm) in rural areas, and 10.4 kg pcpm in urban areas. Rice 
and wheat constitute the bulk of the cereals consumed: in rural areas rice consumption 
averaged 6.8 kg pcpm and that of wheat averaged 4.5 kg pcpm (India 2001). This is why 
in this study the focus is on rice and wheat. Yet, there are distinct geographical patterns in 
dietary intakes: in some regions rice predominates, in others wheat does, and in yet others 
both are consumed. This is summarised in figure 1, which illustrates the composition of 
cereal consumption by state in rural areas. Hence, for our analysis we disaggregated India 
into three dietary regions. As source for information on food consumption, we used a  
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nationally-representative household survey (India 1999/2000). This survey covered over 
100,000 households in both rural and urban areas, and canvassed information on over 140 
individual food items. Individual-specific intakes are, however, not covered and must be 
imputed. By using the unit record data from these surveys, it is possible to use food 
composition tables (Gopalan, Rama Sastri, and Balasubramanian) to derive the corre-
sponding nutrient intakes.
5  
Given this background, biofortifying rice and wheat can be expected to contribute 
significantly to increased iron intakes. However, iron-rich crops are not yet out on the 
farmers’ fields and on the consumers’ plates. Therefore any assessment of a potential 
impact of such an intervention must necessarily be ex-ante in nature. It also depends 
critically on the assumptions made, inter alia, about the likely micronutrient content of 
the new wheat and rice varieties, and their acceptance by farmers and consumers. These 
are indicated in table 3, under both optimistic and pessimistic scenarios, so as to capture 
the range of possible outcomes. The scenarios reflect the expert input of breeders, agro-
nomists, agricultural economists and other scientist at the centres of the Consultative 
Group on International Agricultural Research (CGIAR), who are working on bioforti-
fication research.
6  
According this information, an increase in iron content of 100-167% for rice compared to 
current varieties is deemed to be a reasonable assumption; for wheat the assumed range is 
20-60%. As the additional iron will be bred into the biofortified varieties by means of 
non-transgenic methods, the iron compounds will be the same as in existing varieties and 
there is no reason to assume that the bioavailability of this additional iron changes; it is  
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simply more of the same. For the coming years it is assumed that the “iron trait” will be 
bred into more and more varieties and the estimates of the experts indicate that after 20 
years iron-rich rice can reach a share of 20-50% in total rice production and iron-rich 
wheat can reach a share of 30-50% in total wheat production.
7  
Note that the biofortification strategy explicitly involves breeding nutrient-dense and 
agronomically-superior varieties to facilitate adoption among farmers. As these are 
expected to be developed in collaboration with national agricultural research systems as 
part of ongoing research efforts, seed prices should be unaffected and hence not be a 
deterrent to adoption. Furthermore, given that iron-rich rice and wheat would look and 
taste no different from the present varieties, consumer acceptance should be easy as well. 
Based on these assumptions the iron intake in the “with biofortification”-scenario can be 
computed as follows:  
(5)   new iron intake = total current iron intake +  
    + (current iron intake from crop * percentage increase in iron * production share
8)  
To relate the new (higher) iron intakes to functional outcomes, a further step is necessary. 
One advantage of using unit record data is the possibility to rank intakes from lowest to 
highest and to obtain the cut-off intake level (by inversion) that corresponds to the 
prevalence rates for IDA; any individual with an iron intake below the cut-off level is 
assumed to suffer from the corresponding disease. As illustrated in figure 2, which sets 
out a hypothetical cumulative distribution function for iron intakes, higher intakes imply 
a shifting out to the right of the distribution of intakes. A new, “with biofortification” 
prevalence rate can then be inferred by determining the percentage of people with intakes  
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below the cut-off. The new rate for maternal mortality is derived from the old rate by 
applying the percent decrease stated for severe IDA amongst women. Given these new 
figures, the number of DALYs lost can be recomputed to determine the remaining burden 
of ID. Note that this approach, which utilises information from a representative house-
hold survey, enables a more precise estimate of the likely impact than would be possible 
with the use of average consumption data and an assumed “dose response” function, as is 
done in the aforementioned study by Zimmermann and Qaim on vitamin A deficiency.  
For implementing this method, it is necessary to determine iron intakes by individual 
members of the household. As noted above, the data we use contains only household-
level information. We make the assumption that the food available per household may be 
attributed to its individual members based on their relative energy requirements; that is, 
we established calorie-based adult equivalents. The reasoning is that staples contribute to 
the bulk of calories, and that food is distributed according to the energy requirements of 
household members (rather than according to their iron requirements).
9 The results of this 
exercise yield the new prevalence rates of IDA (table 4). The respective new burdens of 
ID and the differences to the status quo are indicated in table 5.
10  
Even under pessimistic assumptions biofortification of both rice and wheat could save 
1.4m healthy life years every year. The remaining burden of ID would then amount to an 
annual loss of 2.6m DALYs. In this case 36% of the current burden of ID would be 
eliminated. In the optimistic scenario the remaining burden of ID for India would be only 
0.9m DALYs lost per year. This amounts to a decrease of the current burden of ID of 
77%, which represents 3.1m healthy life years that could be saved each year.
11  
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The cost-effectiveness of biofortification 
One of the advantages of biofortification is the absence of major recurrent costs, 
compared to interventions like industrial fortification or pharmaceutical supplementation 
(table 10). Nevertheless, there are initial costs for research and basic breeding efforts for 
the development of the first iron-rich lines; there are marginal costs for testing, for adap-
tive breeding, for dissemination and, to a lesser extent, for extension activities.
12 And 
there are also some continuous marginal costs for maintenance breeding to preserve the 
iron-rich trait. As the basic R&D undertaken is not specifically focused on India alone, 
the resulting iron-rich varieties can be adopted by many more countries and yield benefits 
there. However, as this analysis is to establish the costs and benefits of an intervention 
that is not yet being used, limiting the potential scope and attributing all costs to the 
current main target countries (India, Bangladesh and the Philippines for rice and India 
and Pakistan for wheat) seems to be a conservative approach.
13  
Based on information of the breeders of the CGIAR centres and on the budget in the bio-
fortification programme proposal of CIAT and IFPRI, we established a pessimistic and 
an optimistic scenario for the time frame and costs of biofortification of rice and wheat 
(table 6). Under the pessimistic assumptions the present cost is US$ 17.3m for both crops 
together; the average annual discounted cost amounts to US$ 0.6m, descending from US$ 
1m in the base year to US$ 0.4m in the last year considered. In the optimistic scenario the 
present value of total costs equals US$ 8m and the average present costs per year amount 
to US$ 0.3m, descending from US$ 0.5m in the base year to US$ 0.2m in the last year 
considered.
14   
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Having established the relevant costs that would need to be spent on development, release 
and dissemination of iron-rich rice and wheat, the cost-effectiveness of this new nutrition 
intervention can be determined. In the pessimistic scenario 9.1m DALYs in present terms 
can be saved, while discounted costs equal a net present value of US$ 17.3m. Hence, 
even in the pessimistic scenario the current “price” of saving one healthy life year 
through iron biofortification of both rice and wheat is not even 2 Dollars, namely US$ 
1.90. In the optimistic scenario 22.1m DALYs in present terms can be saved through bio-
fortification, while the net present cost amounts only to US$ 8m. In this case the “price” 
of saving one DALY is only US$ 0.36, i.e. if invested in iron biofortification of rice and 
wheat in India, saving one healthy life year costs only 36 Cents (table 7).  
To put these results into a context: in its World Development Report 1993, the World 
Bank describes costs per DALY saved of about US$ 1 to US$ 3 as “most cost-effective” 
(p. 63). In fact, the report portrays costs of saving one DALY for less than US$ 25 as 
“remarkably low”, and includes activities as “highly cost-effective” that cost between 
US$ 50 and US$ 150 per DALY gained (p. 8). Given this yardstick, iron biofortification 
of rice and wheat proves to be a very cost-effective intervention; even under pessimistic 
assumptions it ranks before all but one of the 47 interventions analysed in the World 
Development Report. Gillespie gives a more specific overview of the cost-effectiveness 
of micronutrient interventions in general and of ID control programmes in particular; he 
quotes figures of US$ 4.4 to US$ 12.8 per DALY saved for iron fortification and 
supplementation programmes respectively. Compared to the cost-effectiveness of these 
other interventions, saving healthy life years through iron biofortification is clearly a very  
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“cheap” approach. The results without discounting of health benefits are even more 
favourable (table 9).
15  
Monetising benefits of biofortification 
The discussion so far has accounted for the benefits in terms of the number of healthy life 
years saved. Indeed, avoiding a reliance on money to measure health benefits is the very 
“beauty” of the DALY concept as it circumvents the ethically dubious exercise of 
attaching a monetary value to human life. However, there are pragmatic reasons to 
ascribe a monetary value to benefits as well as to costs. The most significant of these is 
the need to compare biofortification with other strategies to combat IDA, which often use 
financial indicators. It needs scarcely to be stressed that attaching a monetary value to a 
healthy life year does not entail the intention to determine the intrinsic value of life as 
such. Choosing a value that should be attached to a DALY is a rather arbitrary exercise 
for which there exists no consensus in the literature.
16 We use both US$ 500, which is 
close to India’s per capita income, and US$ 1,000 to convert the number of DALYs 
saved into monetary benefits. Using standard values also facilitates the comparison of our 
results across different countries.  
Carrying out a CBA of iron biofortification of both rice and wheat under the pessimistic 
assumptions and using a DALY value of US$ 500 gives a benefit-cost ratio (BCR) of 264 
and an internal rate of return (IRR) of 74%; in the optimistic scenario the IRR is even 
152%. An overview of these figures, including the results for iron biofortification of rice 
or wheat on their own, and including results for using a DALY value of US$ of 1,000  
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instead of US$ 500, is given in table 8. (The results without discounting of health benefits 
are given in table 9.) These results show clearly that the potential rates of return on 
investments in iron biofortification in the context of India are huge. And this is the case 
even when a DALY is assigned a value of only US$ 500 – a value that certainly fails to 
account for many, if not most, dimensions of health, human happiness and well-being.  
It is useful to compare these results with those of other interventions. One early analysis 
of iron fortification and supplementation (Levin) focused on quantifiable benefits like 
productivity only. He concluded that industrial fortification is advantageous because it 
requires little effort by the target groups and is cheap; BCRs calculated for different 
scenarios and for different developing countries ranged from 5-79 for fortification and 
from 1.6-59 for supplementation. In a more recent overview of micronutrient interven-
tions, Behrman, Alderman and Hoddinott give BCRs of 176-200 for iron fortification and 
of 6.1-14 for supplementation. Looking at the economics of ID in 10 different developing 
countries, Horton and Ross find a BCR for iron fortification programmes of 6-36. How-
ever, they only look at the economic impact of increased productivity and not at the more 
fundamental health benefits per se. Analysing micronutrient programmes in different 
Asian countries, with one exception Horton finds BCRs of 3.6-10.3 for iron supplemen-
tation. Looking at the efficacy of food-based interventions – albeit not biofortification – 
to reduce ID in India, Weinberger (2002) underlines their cost-effectiveness when she 
explains that due to the large number of iron deficient people in India it can be expected 
that food-based approaches to improve their iron status will yield good results at a rela-
tively low cost per person. An analysis that focuses specifically on iron biofortification in  
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India (and Bangladesh) can be found in Bouis: a given monetary value is attached per 
case of anaemia averted and, disregarding potential agricultural benefits, in sum juxta-
posed to the expected costs. The resulting BCRs are in the range of 19-79, and the IRRs 
range from 29-44%.  
Conclusions 
In this article it has become clear that there are already different possible interventions to 
combat micronutrient malnutrition, all of which have their particular strengths, and many 
of which are considered to be cost-effective. Our goal has been to analyse the cost-
effectiveness of a new tool, biofortification, which we did for iron biofortification of rice 
and wheat in India. To measure the potential impact of iron biofortification, we refined 
the methodology of “disability-adjusted life years” (DALYs) to quantify potential health 
benefits of iron-rich rice and wheat, thus analysing an aspect of agricultural technology 
that has so far received little attention: the potential role of plant-breeding in fighting 
micronutrient malnutrition. In doing so we did not only widen the reach of agricultural 
economics to encompass another dimension of health and food security, we also provided 
a knowledge base on which decision makers can build their assessment of this novel 
micronutrient intervention.  
Often health interventions are evaluated based on the economic power and the financial 
capacities of the individuals reached. This has certain ethical limitations. Contrary to 
these methods, the DALY approach does not rely on monetary terms to quantify human 
life and health; it captures the more comprehensive impact of diseases on the ability of  
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people to realise their physical and psychological potential. According to our calcula-
tions, the current burden of iron deficiency (ID) in India amounts to 4m healthy life years 
lost each year. We showed that biofortification, even in a pessimistic scenario, can reduce 
the burden of ID on the Indian population by more than one third. In an optimistic 
scenario this burden would be reduced by more than 75%. Our analysis also showed that 
iron biofortification of rice and wheat is not only effective in reducing the burden of ID, 
but also cost-effective compared to other health interventions. (This cost-effectiveness 
can mainly be explained by the continuous benefit stream that follows the development 
of biofortified rice and wheat, and by the absence of major recurrent costs.) In our pessi-
mistic scenario each 1.90 U.S. Dollars invested in the biofortification programme save 
one healthy life year. In the optimistic scenario the cost of one DALY is even lower: 
saving a healthy life year only costs 36 Cents. Extending this analysis – for pragmatic and 
advocacy reason – to a cost-benefit analysis, the results are just as impressive. In the 
pessimistic scenario we derived an internal rate of return of 74%, while in the optimistic 
scenario this figure even reached 152%. Comparing our results with other studies on 
micronutrient interventions, iron biofortification outperforms alternatives with regard to 
cost-effectiveness and financial indicators.  
The strategy of breeding for micronutrient-dense staple crops is not supposed to solve the 
problem of micronutrient malnutrition for good – the overarching goal is certainly to 
improve and diversify the diets of the poor, if not to lift them out of poverty altogether. 
However, until this long-term objective is reached, this study suggests that iron biofortifi-
cation represents an economically viable intermediate intervention to improve life, health  
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and well-being of millions of people around the globe; there is little doubt that investment 
into biofortification and related research has enormous potential far beyond India. With 
fixed costs for basic R&D, each country where ID is a public health problem and where 
the population eats sufficient quantities of the crop in question only needs to fund and 
carry out adaptive breeding and dissemination to reap health benefits for its population 
for years to come. In this case the assumption is, of course, that the germplasm of bio-
fortified crops is in the public domain. Given that biofortification research is currently 
being carried out at the CGIAR centres this is a likely and promising perspective. Yet, 
benefits will only materialise if biofortified crops are actually eaten by poor consumers 
and peasant farmers. 
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Tables and figures  







Dose  low low low high 










































or private (prices) 
public/donors public/donors 
Monitoring  none  of food processors  none  of implementation 
Intrusion  none (usual diet)*  none (usual diet) 
yes (change of 
diet and customs) 
some (compliance 
in taking pills) 
* In certain instances biofortification may imply a switch from white to orange-fleshed crops.   
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Table 2. Disability Weights used 
Diseases / functional outcomes  Target groups  DA-weights 
children ≤ 5 years, 
and 6-14 years 
0.087  Impaired physical activity  
from severe IDA (sIDA)  women 15+ years, 
and men 15+ years 
0.09 
Impaired physical activity  
from moderate IDA (mIDA) 
all   0.011 
Impaired mental development from sIDA  children ≤ 5 years  0.024 
Impaired mental development from mIDA  children ≤ 5 years  0.006 
Table 3. Assumptions used in the Pessimistic and Optimistic Scenarios 










Iron content in grain  3 ppm (after polishing)  38 ppm  
Potential iron content  6 ppm  8 ppm  46 ppm  61 ppm 
Increase in iron content  100%  167%  20%  60% 
Bioavailability Unchanged 
Share in production 20 
years after release 
20% 50% 30% 50%  
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Table 4. Prevalence of IDA with and without Biofortification of Rice and Wheat 
New prevalence rates of IDA  Current prevalence 
rates of IDA  Pessimistic scenario  Optimistic scenario  Selected target 
groups  Moderate   Severe   Moderate Severe Moderate Severe 
children ≤ 5 years   27.5% 3.2% 23.0% 1.4% 11.0% 0.3% 
women ≥ 15 years  7.4% 1.0% 5.3% 0.3% 1.2% 0.1% 
Table 5. Burden of Iron Deficiency and Potential Gains with Biofortification 
Biofortification 
of  





burden of ID 
(DALYs) 
Rice & wheat  pessimistic  1.4 m  -36%  2.6 m 
Rice & wheat  optimistic  3.1 m  -77%  0.9 m 
Rice  pessimistic  1.2 m  -29%  2.8 m 
Rice  optimistic  2.3 m  -59%  1.7 m 
Wheat  pessimistic  0.3 m   -8%  3.6 m 
Wheat  optimistic  1.1 m   -27%  2.9 m 
* In the status quo 4m DALYs are lost.  
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Table 6. Assumptions used for the Cost and Time Structure of Biofortification R&D  










Basic R&D costs per year  US$ 0.44 m  US$ 0.22 m  US$ 0.55 m  US$ 0.28 m 
Duration of basic R&D  8 years  6 years  9 years  7 years 
Country-specific costs per year  US$ 0.8 m   US$ 0.5 m   US$ 0.8 m   US$ 0.5 m 
Duration of in-country activities  5 years  3 years  7 years  5 years 
Maintenance costs per year, until end 
of the 30 year period considered 
US$ 0.2 m   US$ 0.1 m   US$ 0.2 m   US$ 0.1 m  
Sources: Budget of CIAT and IFPRI, information from breeders and own assumptions. 
Table 7. Cost-Effectiveness of Iron Biofortification of Rice and Wheat 
  Iron biofortification of  
both rice & wheat  only rice  only wheat 
 
US$ per DALY  US$ per DALY  US$ per DALY 
Pessimistic scenario  1.90  1.05  4.86 
Optimistic scenario  0.36  0.21  0.62  
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Table 8. Internal Rates of Return and Benefit-Cost Ratios for Iron Biofortification 
   Iron biofortification of  
  Rice & wheat  Rice  Wheat 
    IRR BCR IRR BCR IRR BCR 
Pessimistic  scenario  74% 264 86% 477 52% 103 
1 DALY =  
US$ 500  Optimistic  scenario 152% 1379 173% 2404 111%  804 
Pessimistic  scenario  88%  527 100% 953  62%  206 
1 DALY =  
US$ 1,000  Optimistic  scenario 180% 2759 204% 4808 131% 1608 
Table 9. Results with and without Discounting of Health Benefits  
With discounting  
of health benefits 
Without discounting  
of health benefits 
Iron biofortification  
of rice and wheat 
pessimistic   optimistic   pessimistic   optimistic  
Loss in status quo  4.0 m DALYs  7.3 m DALYs 
Loss with biofortification  2.6 m DALYs  0.9 m DALYs  4.7 m DALYs  1.7 m DALYs 
DALYs gained   1.4 m DALYs  3.1 m DALYs  2.6 m DALYs  5.5 m DALYs 
Reduction of burden of ID  -36 percent  -77 percent  -35 percent  -76 percent 
Cost per DALY  US$ 1.90  US$ 0.36  US$ 0.54  US$ 0.15 
Internal rate of return   74 percent 152  percent 86  percent 176  percent  
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Table 10. Imputed Costs for India’s Anaemia Control Programme (Tablets only) 
Target group 










w/o severe IDA 
27.4m 50%  100 big 
tablets/case 
5.45 Rs.  US$ 1.6m  
Pregnant women 
with severe IDA 
0.57m 50%  200 big 
tablets/case 
5.45 Rs.  US$ 0.07m 
Children  
aged 1-5 (incl.)  
127.6m 50%  100 small 
tablets/year 
2.5 Rs.  US$ 3.5m 
Hypothetical annual costs for iron and folic acid tablets US$ 5.2m 












































Source: Underlying data taken from India (1999/2000), state-wise disaggregation.  
Figure 1. Cereal Consumption (kg/capita/month) in Rural India, 1999/2000  
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Figure 2. Deriving prevalence rates from intake data 
Endnotes 
                                                 
1 The aetiology of anaemia is multifactorial; however, from a public health perspective ID is believed to be 
the most important causal factor. In the absence of other cheap and simple, yet valid, indicators, anaemia is 
used as a surrogate to estimate the burden of this deficiency. Consequently often the expressions anaemia, 
iron deficiency anaemia and iron deficiency are used interchangeably. Nevertheless, it is important to be 
aware that these 3 terms represent different entities since every case of anaemia is not due to ID and every 
iron deficient subject is not anaemic. 
2 For example, although certain studies suggest that stunting might be a functional outcome of ID (e.g, 
Soewondo, Husaini, and Pollitt; Latham et al.), a recent meta-analysis could not establish a significant 
cause-effect relationship (Ramakrishnan et al.), which is why we did not include stunting. 
3 Allotey et al. give an illustrative account of this criticism, comparing the lives of people suffering from 
paraplegia in different places (rural Cameroon and urban Australia).   
  33
                                                                                                                                                   
4 These 5% are an assumption that was made, because for maternal mortality there are only observational 
data for mortality associated with severe anaemia and not with ID.  
5 We are grateful to R. Sharma for providing us with her computations of iron intakes at the unit record 
level (unpublished PhD dissertation, Delhi School of Economics). These data have been modified to take 
account of the possibility of contamination iron in the food composition values used. For example, in the 
case of milled rice a value of 3 ppm iron is used (G. Barry and P. Virk, personal communication, 2005).  
6 The centres involved are the International Rice Research Institute (IRRI) and the Centro Internacional de 
Mejoramiento de Maíz y Trigo (CIMMYT). The additional expert input was obtained from G. Barry, 
P. Virk, G. Gregorio and J. Rickman of IRRI and from I. Ortiz Monasterio and E. Meng of CIMMYT.  
7 There is also a positive probability that, given the complexities of the underlying genetics and the ex ante 
nature of the analysis, plant breeders will be unable to achieve these nutrient levels within the assumed time 
span. This analysis does not take account of this source of uncertainty as the results would be trivial. 
8 The assumption is that the coverage rates of biofortified rice and wheat translate into production shares, 
which determine the share of biofortified and non-biofortified crops in the individual consumption: because 
they are not distinguishable, iron-rich varieties are assumed to mingle freely with “old” varieties on the 
market. (Producer-consumers are also expected to change only gradually and not fully to the new varieties.)  
9 The results with this set of adult equivalents proved to be very robust when we used adult equivalents that 
were derived in a regression from the data set itself. In this regression the iron intake of the household was 
the dependent variable and the information on household composition (age and gender groups) provided the 
independent variables. Note, however, that because energy and iron requirements differ it is well possible 
(and even likely) that some members within the same household are iron deficient while others are not: for 
example for men, with their relatively low iron requirements, it is easier to cover their iron requirements 
with their relatively big share of food than it is for women. 
10 It is useful to comment on the difference between biofortifying one crop, rather than both: Even though 
there are rice-eating and wheat-eating regions, households consume both cereals to some extent. Therefore, 
if biofortification of one crop already results in iron sufficiency for an individual, biofortifying the other 
crop will not have an additional benefit. Adding up the results for separate biofortification of either rice or 
wheat will lead to double counting and overestimate the potential impact of a combined biofortification  
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programme. Nevertheless, looking at the potential impact of biofortifying one crop only can be enlight-
ening, which is why we also report results for stand-alone biofortification efforts. 
11 India has also a long-standing programme to provide iron and folic acid supplements to young children 
and pregnant women. However, it is generally acknowledged that it has little real impact. It is considered to 
be insufficiently administered, underfunded, and suffering from infrastructure problems and poor compli-
ance (Kapil; Vijayaraghavan; Kapil, Saxena, and Nayar). Therefore we do not expect this programme to 
have an impact that would significantly distort our calculations.  
12 Marginal costs in this context are the costs that have to be incurred to develop and promote the iron-rich 
trait in addition to regular breeding and dissemination costs. Of course the money spent on these activities 
will also influence the ultimate coverage rate of the iron-rich varieties. Yet, in our pessimistic scenario we 
assume higher dissemination and extension costs but a lower adoption rate, while in the optimistic scenario 
we assume lower costs but a higher adoption rate. But these two approaches are only meant to mark the 
very limits of the potential benefits and costs of biofortification. 
13 Based on FAOSTAT data (http://faostat.fao.org/faostat/), if the production shares of all developing coun-
tries in Asia in the respective crops were used as basis to attribute the R&D costs at the international level, 
India’s share would sink from 70.5 to 23.2% for rice and from 78.5 to 31.7% for wheat.  
14 In comparison, the annual costs only for the iron and folic acid tablets of India’s iron supplementation 
programme (see Endnote 11), with its limited scope and target coverage, would amount to US$ 5.2m if the 
programme was completely implemented (Table 10).  
15 Another way to look at the costs of biofortification is to attribute costs on a per capita basis. In the pessi-
mistic scenario this is US$ 0.0006 per capita only and in the optimistic scenario it is US$ 0.0003. 
16 Recent studies that used DALYs in the context of developing countries resorted to standardised rates of 
US$ 1000 or US$ 500 per DALY; in other cases the economic potential of the country was used as basis 
and a DALY was valued at per capita income (Collier and Hoeffler; Rijsberman; Mills and Shillcutt; 
Behrman, Alderman, and Hoddinott; Appleton; and Zimmermann and Qaim).  